XP-102: A prodrug (small molecule drug conjugate) was designed to enhance the efficacy of radiation therapy in solid tumors such as pancreatic cancer. This prodrug leverages PolyAdvant's innovative approach to activate anticancer prodrugs through radiotherapy, ensuring precise targeting and low toxicity.

XPADC-106: A prodrug (antibody drug conjugate) focus on solid tumors such as HNSCC and lung cancer. XPADC-106 shows PolyAdvant's commitment to diversifying the selection of active ingredients, providing more treatment options and enhancing the potential for synergistic therapeutic effects with radiation.